Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-10
Freeman Chris Files Guardant Health (GH) Form 4 - August 10, 2026
Freeman Chris traded 127.2K GH shares worth $15.5M in this Form 4 filing, reported to the SEC on 2026-08-10.
- Insider
- Freeman Chris
- Issuer
- Guardant Health Inc. GH · NASDAQ
- Filed
- Period
- 2026-08-10
- Accession
- 0001871615-26-000016
- Source
- Official filing on sec.gov ↗
Transactions (8)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Freeman Chris | 2026-08-10 | Buy | 35.4K | $110.49 | $3.9M | Direct |
| Freeman Chris | 2026-08-10 | Buy | 28.2K | $28.37 | $799.8K | Direct |
| Freeman Chris | 2026-08-10 | Sell | 3.5K | $167.38 | $579.6K | Direct |
| Freeman Chris | 2026-08-10 | Sell | 7.4K | $168.79 | $1.2M | Direct |
| Freeman Chris | 2026-08-10 | Sell | 35.4K | $169.63 | $6.0M | Direct |
| Freeman Chris | 2026-08-10 | Sell | 17.4K | $170.24 | $3.0M | Direct |
| Net change | 0 | −$6.1M | ||||
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Track GH insider activity
Get alerted when Guardant Health Inc. executives buy or sell their shares.